A trial of unrelated donor marrow transplantation for children with severe sickle cell disease

Children with sickle cell disease experience organ damage, impaired quality of life, and premature mortality. Allogeneic bone marrow transplant from an HLA-matched sibling can halt disease progression but is limited by donor availability. A Blood and Marrow Transplant Clinical Trials Network (BMT CT...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2016-11, Vol.128 (21), p.2561-2567
Main Authors: Shenoy, Shalini, Eapen, Mary, Panepinto, Julie A., Logan, Brent R., Wu, Juan, Abraham, Allistair, Brochstein, Joel, Chaudhury, Sonali, Godder, Kamar, Haight, Ann E., Kasow, Kimberly A., Leung, Kathryn, Andreansky, Martin, Bhatia, Monica, Dalal, Jignesh, Haines, Hilary, Jaroscak, Jennifer, Lazarus, Hillard M., Levine, John E., Krishnamurti, Lakshmanan, Margolis, David, Megason, Gail C., Yu, Lolie C., Pulsipher, Michael A., Gersten, Iris, DiFronzo, Nancy, Horowitz, Mary M., Walters, Mark C., Kamani, Naynesh
Format: Article
Language:English
Subjects:
Adolescent
Allografts
Anemia, Sickle Cell - mortality
Anemia, Sickle Cell - physiopathology
Anemia, Sickle Cell - therapy
Bone Marrow Transplantation
Calcineurin Inhibitors - administration & dosage
Child
Disease-Free Survival
Female
Follow-Up Studies
Graft vs Host Disease - mortality
Graft vs Host Disease - prevention & control
Humans
Male
Survival Rate
Transplantation
Unrelated Donors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Children with sickle cell disease experience organ damage, impaired quality of life, and premature mortality. Allogeneic bone marrow transplant from an HLA-matched sibling can halt disease progression but is limited by donor availability. A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) phase 2 trial conducted from 2008 to 2014 enrolled 30 children aged 4 to 19 years; 29 were eligible for evaluation. The primary objective was 1-year event-free survival (EFS) after HLA allele-matched (at HLA-A, -B, -C, and -DRB1 loci) unrelated donor transplant. The conditioning regimen included alemtuzumab, fludarabine, and melphalan. Graft-versus-host disease (GVHD) prophylaxis included calcineurin inhibitor, short-course methotrexate, and methylprednisolone. Transplant indications included stroke (n = 12), transcranial Doppler velocity >200 cm/s (n = 2), ≥3 vaso-occlusive pain crises per year (n = 12), or ≥2 acute chest syndrome episodes (n = 4) in the 2 years preceding enrollment. Median follow-up was 26 months (range, 12-62 months); graft rejection was 10%. The 1- and 2-year EFS rates were 76% and 69%, respectively. The corresponding rates for overall survival were 86% and 79%. The day 100 incidence rate of grade II-IV acute GVHD was 28%, and the 1-year incidence rate of chronic GVHD was 62%; 38% classified as extensive. There were 7 GVHD-related deaths. A 34% incidence of posterior reversible encephalopathy syndrome was noted in the first 6 months. Although the 1-year EFS met the prespecified target of ≥75%, this regimen cannot be considered sufficiently safe for widespread adoption without modifications to achieve more effective GVHD prophylaxis. The BMT CTN #0601 trial was registered at www.clinicaltrials.gov as #NCT00745420. •Children with sickle cell disease engrafted unrelated donor marrow after reduced intensity conditioning.•A high incidence of GVHD and associated mortality compromised safety of the trial.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2016-05-715870